HR 7693, "Leo’s Law," extends existing exclusivity protections for certain orphan drugs by 180 days to address pandemic-related delays. It applies to drugs designated for rare diseases that had applications submitted during the COVID-19 emergency period (Dec 2019-March 2023), were approved under specific pathways, and have no non-rare disease indications. Key provisions extend periods like the 12-year market exclusivity under the Public Health Service Act and 5-year protections under the Federal Food, Drug, and Cosmetic Act. The bill does not create new incentives but temporarily lengthens existing protections for drug developers already navigating pandemic disruptions. This change applies only to qualifying orphan drugs meeting all specified criteria during the defined emergency period.
HR 7417 reauthorizes and expands the WISEWOMAN program to include heart health screenings and education for low-income women. The bill directs the CDC to award grants for blood pressure and cholesterol screenings, health education, and referrals for heart disease prevention, building on existing breast and cervical cancer services. It specifically targets low-income women who are already served by the WISEWOMAN program or meet new eligibility criteria set by the Secretary. The expansion is funded with $250 million over five fiscal years (2027-2031), with services to be provided by current WISEWOMAN grantees or approved alternative providers.
The Nurse Corps Tax Parity Act of 2025 ensures that certain payments and scholarships for nurses in the National Health Service Corps (NHSC) are excluded from federal income tax, matching the tax treatment of similar benefits under existing programs. It updates two key tax code provisions to include the Nurse Corps scholarship program (under section 846 of the Public Health Service Act) in the list of qualifying programs for tax exemption. This directly affects nurses and students receiving NHSC payments or scholarships as part of their service commitments. The bill creates tax parity by removing a potential tax burden for participants, aligning their benefits with other healthcare workforce programs.
HR 7227, the Mental Health and MAMA Act of 2026, eliminates cost-sharing (like copays or deductibles) for mental health and substance use treatment services during pregnancy and for one year after childbirth. It directly affects pregnant and postpartum individuals covered by group health plans or individual insurance policies, requiring these plans to cover such services with no out-of-pocket costs from pregnancy diagnosis through the 12-month period following birth. The law applies to in-network providers and includes telehealth services, with implementation delayed until two years after enactment. It amends key laws including the Public Health Service Act, ERISA, and the Internal Revenue Code to standardize this coverage requirement across health insurance systems. This policy change aims to improve access to care during a critical health period without altering existing coverage definitions.
This bill amends an existing fellowship program under the Public Health Service Act to specifically include "addiction medicine" as a qualifying specialty. It modifies Section 597 to expand the program's scope, allowing medical professionals training in addiction medicine to participate in the Minority Fellowship Program. The change directly affects physicians and medical trainees seeking fellowship opportunities in addiction medicine, particularly those from underrepresented groups, by making this specialty eligible for the program. The bill does not create new funding or programs but adjusts the existing program's eligibility criteria.
The Choose Medicare Act would establish a new Medicare Part E public health plan available across individual, small group, and large group insurance markets. This plan would provide comprehensive coverage including all essential health benefits, gold-level coverage, and reproductive services, with premiums negotiated to be at least as favorable as current Medicare rates. The bill would create a $6,700 annual out-of-pocket spending limit for Medicare beneficiaries starting in 2027, require employers to refer employees without adequate coverage to navigators, and change premium assistance credits to use gold-level plans as the benchmark. It would also establish a $2 billion startup fund for the program and expand reduced cost-sharing for lower-income individuals.
The Dietary Guidelines Reform Act of 2025 changes how the federal government develops the Dietary Guidelines for Americans, which are used to inform nutrition policies and public health programs. It requires guidelines to be based on the latest scientific evidence, address chronic diseases, and ensure recommendations are affordable and accessible for all Americans. The bill establishes an Independent Advisory Board with specific membership rules (including political balance and scientific expertise) and mandates full disclosure of conflicts of interest for all members. It also sets a 10-year update cycle for the guidelines but allows for more frequent updates when scientific advancements require it, with justification provided to Congress.
HR 2414 reauthorizes a grant program that connects military and civilian healthcare systems to improve trauma care readiness. It extends the program's funding period from fiscal years 2025 through 2029 (replacing the previous 2019-2023 authorization). The bill directly affects military medical facilities and civilian trauma centers receiving these grants. It makes no changes to the program's purpose or eligibility, only extending the timeframe for funding. This is a procedural extension of an existing grant program under the Public Health Service Act.
This bill would add pharmacist services to Medicare Part B coverage for beneficiaries, specifically covering pharmacist-led testing and treatment for illnesses like flu, COVID-19, or strep throat during public health emergencies. It defines covered services as those performed under state law, often requiring collaboration with a physician, and sets payment at 80% of the lesser of the actual charge or 85% of physician payment rates. Pharmacists would be prohibited from balance billing for these services, ensuring Medicare beneficiaries pay only their standard copayment. The changes would take effect January 1, 2026.
This bill makes payments to clinical trial participants tax-free and ensures those payments won't count toward income limits for federal programs like Medicaid or food assistance. It covers both compensation for participation and reimbursement of reasonable expenses (like travel) related to approved clinical trials for life-threatening conditions. The exclusion applies to payments made after December 31, 2025, and is defined in the bill using existing IRS and Public Health Service Act terms.